Galectins and Carcinogenesis: Their Role in Head and Neck Carcinomas and Thyroid Carcinomas

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2017 Dec 21

PMID 29258258

Citations 11

Authors

Nadege Kindt

Fabrice Journe

Ghanem E Ghanem

Sven Saussez

Affiliations

Soon will be listed here.

Abstract

Head and neck cancers are among the most frequently occurring cancers worldwide. Of the molecular drivers described for these tumors, galectins play an important role via their interaction with several intracellular pathways. In this review, we will detail and discuss this role with specific reference to galectins-1, -3, and -7 in angiogenesis, cell proliferation, and invasion as well as in cell transformation and cancer progression. Furthermore, we will evaluate the prognostic value of galectin expression in head and neck cancers including those with oral cavity, salivary gland, and nasopharyngeal pathologies. In addition, we will discuss the involvement of these galectins in thyroid cancers where their altered expression is proposed as a new diagnostic biomarker.

Citing Articles

CD71 erythroid cells suppress T-cell effector functions and predict immunotherapy outcomes in patients with virus-associated solid tumors.

Bozorgmehr N, Okoye I, Mashhouri S, Lu J, Koleva P, Walker J J Immunother Cancer. 2023; 11(5).

PMID: 37236637 PMC: 10230995. DOI: 10.1136/jitc-2022-006595.

Head and neck cancer N-glycome traits are cell line and HPV status-dependent.

Rasheduzzaman M, Murugan A, Zhang X, Oliveira T, Dolcetti R, Kenny L Anal Bioanal Chem. 2022; 414(29-30):8401-8411.

PMID: 36289103 PMC: 9712327. DOI: 10.1007/s00216-022-04376-x.

Myeloid Cells Are Enriched in Tonsillar Crypts, Providing Insight into the Viral Tropism of Human Papillomavirus.

Mattox A, Roelands J, Saal T, Cheng Y, Rinchai D, Hendrickx W Am J Pathol. 2021; 191(10):1774-1786.

PMID: 34303699 PMC: 8491092. DOI: 10.1016/j.ajpath.2021.06.012.

Reduced Expression of Galectin-8 May Contribute in Carcinogenic Pathway of Head and Neck Squamous Cell Carcinoma.

Ghasemi M, Vahedi Larijani L, Yazdani-Charati J, Kamali Hakim E Iran J Pathol. 2021; 16(2):195-204.

PMID: 33936231 PMC: 8085289. DOI: 10.30699/IJP.2021.121140.2318.

Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors.

Okoye I, Xu L, Motamedi M, Parashar P, Walker J, Elahi S J Immunother Cancer. 2020; 8(2).

PMID: 33310773 PMC: 7735134. DOI: 10.1136/jitc-2020-001849.

References

Kovacs-Solyom F, Blasko A, Fajka-Boja R, Katona R, Vegh L, Novak J . Mechanism of tumor cell-induced T-cell apoptosis mediated by galectin-1. Immunol Lett. 2009; 127(2):108-18. DOI: 10.1016/j.imlet.2009.10.003. View

Sumana B, Shashidhar S, Shivarudrappa A . Galectin-3 Immunohistochemical Expression in Thyroid Neoplasms. J Clin Diagn Res. 2015; 9(11):EC07-11. PMC: 4668414. DOI: 10.7860/JCDR/2015/16277.6760. View

DAlessandria C, Braesch-Andersen S, Bejo K, Reder S, Blechert B, Schwaiger M . Noninvasive In Vivo Imaging and Biologic Characterization of Thyroid Tumors by ImmunoPET Targeting of Galectin-3. Cancer Res. 2016; 76(12):3583-92. DOI: 10.1158/0008-5472.CAN-15-3046. View

Saussez S, Lorfevre F, Lequeux T, Laurent G, Chantrain G, Vertongen F . The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncol. 2007; 44(1):86-93. DOI: 10.1016/j.oraloncology.2006.12.014. View

Suzuki Y, Sutoh M, Hatakeyama S, Mori K, Yamamoto H, Koie T . MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis. Int J Oncol. 2012; 40(6):1831-8. PMC: 3396290. DOI: 10.3892/ijo.2012.1411. View

Tang W, Huang C, Tang C, Xu J, Wang H . Galectin-3 may serve as a potential marker for diagnosis and prognosis in papillary thyroid carcinoma: a meta-analysis. Onco Targets Ther. 2016; 9:455-60. PMC: 4730995. DOI: 10.2147/OTT.S94514. View

Liu F, Patterson R, Wang J . Intracellular functions of galectins. Biochim Biophys Acta. 2002; 1572(2-3):263-73. DOI: 10.1016/s0304-4165(02)00313-6. View

Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim H, Raz A . Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem. 2001; 277(9):6852-7. DOI: 10.1074/jbc.M107668200. View

Saussez S, Cucu D, Decaestecker C, Chevalier D, Kaltner H, Andre S . Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer. Ann Surg Oncol. 2006; 13(7):999-1009. DOI: 10.1245/ASO.2006.08.033. View

10.

. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014; 159(3):676-90. PMC: 4243044. DOI: 10.1016/j.cell.2014.09.050. View

11.

Rubinstein N, Alvarez M, Zwirner N, Toscano M, Ilarregui J, Bravo A . Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell. 2004; 5(3):241-51. DOI: 10.1016/s1535-6108(04)00024-8. View

12.

Demotte N, Bigirimana R, Wieers G, Stroobant V, Squifflet J, Carrasco J . A short treatment with galactomannan GM-CT-01 corrects the functions of freshly isolated human tumor-infiltrating lymphocytes. Clin Cancer Res. 2014; 20(7):1823-33. DOI: 10.1158/1078-0432.CCR-13-2459. View

13.

. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015; 517(7536):576-82. PMC: 4311405. DOI: 10.1038/nature14129. View

14.

Yan G, Zou R, Chen Z, Fan B, Wang Z, Wang Y . Silencing RhoA inhibits migration and invasion through Wnt/β-catenin pathway and growth through cell cycle regulation in human tongue cancer. Acta Biochim Biophys Sin (Shanghai). 2014; 46(8):682-90. DOI: 10.1093/abbs/gmu051. View

15.

Chen C, Duckworth C, Zhao Q, Pritchard D, Rhodes J, Yu L . Increased circulation of galectin-3 in cancer induces secretion of metastasis-promoting cytokines from blood vascular endothelium. Clin Cancer Res. 2013; 19(7):1693-704. PMC: 3618858. DOI: 10.1158/1078-0432.CCR-12-2940. View

16.

Xu Y, Li C, Sun J, Li J, Gu X, Xu W . Antitumor effects of galectin-3 inhibition in human renal carcinoma cells. Exp Biol Med (Maywood). 2016; 241(13):1365-73. PMC: 4994919. DOI: 10.1177/1535370216630839. View

17.

Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf J, Shah R . Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016; 126(3):1052-66. PMC: 4767360. DOI: 10.1172/JCI85271. View

18.

Pazaitou-Panayiotou K, Polyzos S, Mantzoros C . Obesity and thyroid cancer: epidemiologic associations and underlying mechanisms. Obes Rev. 2013; 14(12):1006-22. DOI: 10.1111/obr.12070. View

19.

Kim E, Lim D, Lee K, Jung C, Bae J, Jung S . Absence of galectin-3 immunostaining in fine-needle aspiration cytology specimens from papillary thyroid carcinoma is associated with favorable pathological indices. Thyroid. 2012; 22(12):1244-50. DOI: 10.1089/thy.2011.0166. View

20.

Thijssen V, Postel R, Brandwijk R, Dings R, Nesmelova I, Satijn S . Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A. 2006; 103(43):15975-80. PMC: 1635112. DOI: 10.1073/pnas.0603883103. View